Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation
- PMID: 2154620
- PMCID: PMC249265
- DOI: 10.1128/JVI.64.3.1398-1401.1990
Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation
Abstract
The ability of B cells, B blasts, and macrophages to present Epstein-Barr virion antigens to autologous T cells and trigger their capacity to inhibit Epstein-Barr virus-induced B-cell transformation was tested. Macrophages were as efficient as B cells and B blasts in presenting the virus to T lymphocytes. This function required antigen processing, because it was inhibited by chloroquine treatment and by fixation of the antigen-presenting cells immediately after viral exposure but not 18 h later. T cells exposed to the purified Epstein-Barr virus envelope antigen gp350 coupled to immunostimulating complexes also showed inhibitory function. These results suggest that recognition of processed virion antigens elicits the generation of T-cell-mediated inhibition of Epstein-Barr virus-induced B-cell transformation.
Similar articles
-
Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.J Exp Med. 2006 Apr 17;203(4):995-1006. doi: 10.1084/jem.20051287. Epub 2006 Mar 20. J Exp Med. 2006. PMID: 16549597 Free PMC article.
-
Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells.J Immunol. 1982 Oct;129(4):1446-50. J Immunol. 1982. PMID: 6286767
-
MHC class II-restricted presentation of endogenously synthesized antigen: Epstein-Barr virus transformed B cell lines can present the viral glycoprotein gp340 by two distinct pathways.Int Immunol. 1993 May;5(5):451-60. doi: 10.1093/intimm/5.5.451. Int Immunol. 1993. PMID: 8391306
-
Cell-mediated immunity against Epstein-Barr virus infected B lymphocytes.Springer Semin Immunopathol. 1982;5(1):63-73. doi: 10.1007/BF00201957. Springer Semin Immunopathol. 1982. PMID: 6314570 Review. No abstract available.
-
T cell recognition of Epstein-Barr virus associated lymphomas.Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
Cited by
-
Control of viral disease: the development of Epstein-Barr virus vaccines.Springer Semin Immunopathol. 1991;13(2):249-62. doi: 10.1007/BF00201472. Springer Semin Immunopathol. 1991. PMID: 1664989 Review. No abstract available.
-
Gammaherpesviruses and B Cells: A Relationship That Lasts a Lifetime.Viral Immunol. 2020 May;33(4):316-326. doi: 10.1089/vim.2019.0126. Epub 2020 Jan 8. Viral Immunol. 2020. PMID: 31913773 Free PMC article. Review.
-
Immune regulation in Epstein-Barr virus-associated diseases.Microbiol Rev. 1995 Sep;59(3):387-405. doi: 10.1128/mr.59.3.387-405.1995. Microbiol Rev. 1995. PMID: 7565411 Free PMC article. Review.
-
Failure of Epstein-Barr virus-specific cytotoxic T lymphocytes to lyse B cells transformed with the B95-8 strain is mapped to an epitope that associates with the HLA-B8 antigen.Clin Exp Immunol. 1992 Jan;87(1):65-70. doi: 10.1111/j.1365-2249.1992.tb06414.x. Clin Exp Immunol. 1992. PMID: 1370774 Free PMC article.
-
Engineered nanoparticles for precise targeted drug delivery and enhanced therapeutic efficacy in cancer immunotherapy.Acta Pharm Sin B. 2024 Aug;14(8):3432-3456. doi: 10.1016/j.apsb.2024.05.010. Epub 2024 May 13. Acta Pharm Sin B. 2024. PMID: 39220871 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources